HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Spiramycin

A macrolide antibiotic produced by Streptomyces ambofaciens. The drug is effective against gram-positive aerobic pathogens, N. gonorrhoeae, and staphylococci. It is used to treat infections caused by bacteria and Toxoplasma gondii.

Also Known As:

Antibiotic 799; Aventis Brand of Spiramycin; Grünenthal Brand of Spiramycin; IL-5902; NSC-55926; NSC-64393; Rhône-Poulenc Rorer Brand of Spiramycin; Rovamycin; Rovamycine; Selectomycin; Spiramycine; Teofarma Brand of Spiramycin; IL 5902; IL5902; NSC 55926; NSC 64393; NSC55926; NSC64393; Spiramycin Adipate

Networked: 339 relevant articles (40 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Masini, L: 2 articles (02/2015 - 03/2009)
2.	Valentini, P: 2 articles (02/2015 - 03/2009)
3.	Speziale, D: 2 articles (02/2015 - 03/2009)
4.	Costa, Tatiane L: 2 articles (01/2014 - 01/2014)
5.	Avelino, Mariza M: 2 articles (01/2014 - 01/2014)
6.	Amaral, Waldemar N: 2 articles (01/2014 - 01/2014)
7.	Castro, Ana M: 2 articles (01/2014 - 01/2014)
8.	Barbosa, B F: 2 articles (11/2011 - 10/2009)
9.	Silva, D A O: 2 articles (11/2011 - 10/2009)
10.	Mineo, J R: 2 articles (11/2011 - 10/2009)

Related Diseases

1.	Infection 08/11/1990 - "The major flaw is that the efficacy of spiramycin in preventing contamination of the fetus, or at least in reducing the extent of the infection, has never been evaluated in a randomised placebo-controlled clinical trial. " 06/01/2014 - "Spiramycin is effective in treating of Cryptosporidium infection." 07/01/1988 - "Spiramycin has been found to be effective in a variety of clinical and experimental infections despite modest in-vitro activity. " 08/01/1987 - "The authors conclude that spiramycin adipate constitutes an appropriate first-line treatment of acute bronchial and/or pulmonary infections in adults. " 08/01/1962 - "It is suggested that the efficacy of spiramycin against experimental infections is due to its persistence in the animal body."
2.	Toxoplasmosis 07/01/2012 - "The results of our study suggested that there might be synergy between beta-glucan and spiramycin in the treatment of acute toxoplasmosis." 07/01/2012 - "Within the reach of our literature survey, this study is the first research in which the effectiveness of the combination of beta-glucan and spiramycin in the treatment of acute toxoplasmosis was investigated. " 11/20/2015 - "Streptomyces ambofaciens ATCC23877 is a soil bacterium industrially exploited for the production of the macrolide spiramycin which is used in human medicine as an antibacterial and anti-toxoplasmosis chemical. " 01/01/2014 - "Eligible participants were divided into 2 groups: group 1 consisted of 44 newborns born to mothers treated with spiramycin during pregnancy and group 2 consisted of 24 newborns born to mothers not treated with spiramycin during pregnancy because the diagnosis of toxoplasmosis was not performed. " 01/01/2014 - "We aimed to evaluate whether treatment of pregnant women with spiramycin associated with a lack of monitoring for toxoplasmosis seroconversion affects the prognosis of patients. "
3.	Diarrhea 03/01/1989 - "The efficacy of spiramycin was evaluated in a double blind, placebo-controlled study of 44 immunocompetent infants ages 2 to 13 months who had acute diarrhea caused by Cryptosporidium. " 05/01/1993 - "[Chronic diarrhea due to Cryptosporidium: the efficacy of spiramycin treatment]." 04/01/1990 - "Other family members suffered from chronic undiagnosed diarrhea, and resolution occurred only after a trial of spiramycin. " 01/01/1989 - "Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial." 05/01/1993 - "Spiramycin seems to be an effective and well-tolerated drug: treatment is recommended in children with prolonged and/or severe diarrhea when Cryptosporidium seems to be the etiological cause of the disease."
4.	Periodontitis 01/01/1970 - "[The therapeutic treatment of periodontitis with spiramycin]." 08/01/2011 - "In vitro spiramycin resistance among putative periodontal pathogens of United States origin occurred in approximately one-half of severe periodontitis patients evaluated, particularly among subgingival F. " 08/01/2011 - "Spiramycin resistance in human periodontitis microbiota." 01/01/2011 - "These data indicate that bacteria currently associated with advanced periodontitis (Pg, Tf and Td) are suppressed after 7 days of systemic administration of Spiramycin." 03/01/1994 - "The effects of spiramycin and/or scaling on advanced periodontitis in humans."
5.	Congenital Toxoplasmosis 08/01/2004 - "Treatment with spiramycin was effective in preventing congenital toxoplasmosis in children of sero-positive mothers who consented to treatment." 05/01/1998 - "Congenital toxoplasmosis: efficacy of maternal treatment with spiramycin alone." 01/01/2014 - "The purpose of this study was to assess methods for the confirmation of congenital toxoplasmosis after maternal treatment with spiramycin during pregnancy, and to evaluate the effect of this treatment on clinical manifestations of the disease in newborns (NB). " 01/01/2014 - "Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy." 11/01/1996 - "[Prevention of congenital toxoplasmosis with spiramycin; value and limits of levels in amniotic fluid]."

Related Drugs and Biologics

1.	Erythromycin (Erycette)
2.	Metronidazole (Metric)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Tetracycline (Achromycin)
5.	Azithromycin (Zithromax)
6.	Amoxicillin (Wymox)
7.	Penicillin G Procaine (Procaine, Benzylpenicillin)
8.	Clindamycin (Cleocin)
9.	Clarithromycin (Biaxin)
10.	Macrolides

Related Therapies and Procedures

1.	Root Planing
2.	Aftercare (After-Treatment)
3.	Subcutaneous Injections
4.	Intramuscular Injections
5.	Intravenous Infusions